摘要
到目前为止,脓毒血症的发病机制以及影响疾病转归和病死率的因素均尚不明确。由于发病前没有典型的风险预测,所以早期诊断和危险分级非常困难,这些因素使脓毒血症在发病前无法得到快速、有效的治疗。生物标志物(如C反应蛋白和降钙素原)通常作为决定临床治疗方案的辅助指标,而除了这些急性期蛋白,还有很多物质对脓毒血症的诊断和预后评估具有潜在价值。
So far exact mechanisms and variables determining outcome and mortality of sepsis stay unclear. Since there is no typical risk profile, early diagnosis and risk stratification remain difficult which hin- ders the rapid and effective treatment before onset. Biomarkers like C-reactive protein and procalcitonin are routinely used as complementary tools in clinical decision-making. Beyond these acute phase proteins, a wide bunch of substances with potential diagnostic and prognostic value is under intensive investigation.
出处
《医学综述》
2016年第15期2942-2946,共5页
Medical Recapitulate